Conjugated linoleic acid: a functional nutrient in the different pathophysiological components of the metabolic syndrome?
- 1 November 2006
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 9 (6), 740-747
- https://doi.org/10.1097/01.mco.0000247465.34037.05
Abstract
Much attention has focused on the therapeutic potential of conjugated linoleic acid with the most abundant isomers being cis-9,trans-11 conjugated linoleic acid and trans-10,cis-12 conjugated linoleic acid. Initial animal studies associated conjugated linoleic acid with beneficial health properties, such as reducing the risk of cancer, diabetes, atherosclerosis, inflammation and obesity. This review has appraised the evidence in relation to the effect of conjugated linoleic acid on components of the metabolic syndrome (clinically or experimentally), in particular, obesity, insulin resistance, atherosclerosis and inflammation. More recent human conjugated linoleic acid supplementation studies have often shown conflicting and less convincing health benefits. The marked variation between studies may reflect the isomer-specific effect of the individual conjugated linoleic acid isomers, which can often have opposing effects. Detrimental effects have been observed in some studies, in particular after supplementation with the trans-10,cis-12 conjugated linoleic acid isomer. Further studies and long-term clinical trials will be required to determine the efficacy and safety of conjugated linoleic acid isomers before conjugated linoleic acid could be considered as a functional nutrient in humans.Keywords
This publication has 79 references indexed in Scilit:
- Genetic and nutrient determinants of the metabolic syndromeCurrent Opinion in Cardiology, 2006
- How to best define the metabolic syndromeAnnals of Medicine, 2006
- Fatty acids, inflammation, and the metabolic syndromeThe American Journal of Clinical Nutrition, 2005
- Functional foods in the management of obesity and type 2 diabetesCurrent Opinion in Clinical Nutrition and Metabolic Care, 2005
- LIPGENE: an integrated approach to tackling the metabolic syndrome.Proceedings of the Nutrition Society, 2005
- The prevalence and costs of obesity in the EUProceedings of the Nutrition Society, 2005
- The metabolic syndrome: the crossroads of diet and geneticsProceedings of the Nutrition Society, 2005
- New drug targets for type 2 diabetes and the metabolic syndromeNature, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Jama-Journal Of The American Medical Association, 2001
- Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO ConsultationDiabetic Medicine, 1998